Amicus Therapeutics, a Leader in Compassionate Care of Human Genetic Diseases

Amicus Therapeutics is a company located in Cranbury, New Jersey. The focus of the company is compassionate care and therapies of rare orphan human genetic diseases (Google Finance).


Amicus Therapeutics has been given grants by The Michael J. Fox Foundation, and the Alzheimer’s Drug Discovery Foundation, to support further research into Alzheimer’s and Parkinson’s diseases.


Amicus Therapeutics has a great passion for the diseases they study, and for the patients that they serve. They have a patient advocacy program, where they aid and assist both patients and their families every step of the way throughout the disease process. This is a feather in Amicus Therapeutics’ cap, showing that their range of compassion extends far beyond the research process. These are people who really do care, and see their patients as true people, not just as research.


The staff of Amicus Therapeutics is available to assist in all aspects of the disease experience, both great and small, and to be true advocates for patients and their families, wherever and whenever the need arises.


Amicus Therapeutics has even put together a patient advisory board, which consists of members of patients going through the disease experience, who are well informed, and wish to collectively share their experience with other patients regarding any aspects of the disease experience. This is a great communication tool, also furthering knowledge and research of both Amicus Therapeutics and the patients and their families.


Amicus Therapeutics is an outstanding company, who strives to rise above the rest ( The people who work there believe in their patients and in what they do. They strive to think differently. They take calculated risks, but also learn from their mistakes, and grow in the process. They strive to be the best in research and compassionate care. They support the research of the disease, the disease communities, their patients, and their patients’ families, and work to be the best in rare human genetic and orphan disease research.